The proposed studies focus on central nervous system (CNS) HIV infection and its consequences in treated patients with plasma viral suppression. In the first of two aims, we will use the ultrasensitive single copy assay (SCA) of viral RNA to define the presence and magnitude of cerebrospinal fluid (CSF) infection in a group of 'well-treated'patients and examine the impact of 'residual'CSF infection on CSF biomarkers of immunoactivation and neural injury and on neuropsychological test performance. We will also assess whether residual CSF infection relates to combination drug penetration characteristics. In the second aim, we will use sensitive single genome sequencing (SGS) methods and phylogenetic relationships to analyze the origins of viral escape and residual CSF HIV in treated patients. While antiretroviral therapy has had a remarkable impact on severe CNS HIV disease, persistent CNS infection in treated patients remains potentially important as the driver of chronic, continued CNS immunoactivation and injury, and as a viral reservoir that needs to be targeted by viral eradication strategies. The proposed studies will provide unique and essential information regarding the frequency, character and consequences of continued CNS HIV infection in 'well-treated'patients and also provide a foundation for eradication strategies targeting this infection.
While antiretroviral therapy has effectively reduced the more severe neurological complications of HIV infection, central nervous system (CNS) infection by HIV unfortunately remains important in treated patients. Patients continue to show evidence of milder, but still important, neurocognitive impairment along with immunological abnormalities and breakthrough of infection in the cerebrospinal fluid (CSF), suggesting continued infection in the nervous system, and, as treatment approaches begin to extend to strategies for viral eradication or cure, this CNS infection may prove a limiting factor. After applying very sensitive viral detection methods to CSF in order to further define the presence of HIV infection in 'well-treated'patients, the results of these studies will provide novel and important information regarding the persistence of HIV and its effects on the CNS despite treatment, as well as methods for evaluating the CNS effects of future eradication strategies.
|GisslÃ©n, Magnus; Price, Richard W; Andreasson, Ulf et al. (2016) Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 3:135-40|
|Price, Richard W; Spudich, Serena S; Peterson, Julia et al. (2014) Evolving character of chronic central nervous system HIV infection. Semin Neurol 34:7-13|
|Peterson, Julia; Gisslen, Magnus; Zetterberg, Henrik et al. (2014) Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One 9:e116081|
|Dahl, Viktor; Peterson, Julia; Fuchs, Dietmar et al. (2014) Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS 28:2251-8|
|Jessen Krut, Jan; Mellberg, Tomas; Price, Richard W et al. (2014) Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One 9:e88591|
|Dahl, Viktor; Gisslen, Magnus; Hagberg, Lars et al. (2014) An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis 209:1618-22|
|Price, Richard W; Peterson, Julia; Fuchs, Dietmar et al. (2013) Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol 8:1147-58|
|Dahl, Viktor; Peterson, Julia; Spudich, Serena et al. (2013) Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS 27:1145-9|
|Yukl, Steven A; Boritz, Eli; Busch, Michael et al. (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 9:e1003347|